Stock TVTX TRAVERE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
6.34 USD +0.63% Intraday chart for Travere Therapeutics, Inc. -3.21% -29.48%
May. 07 Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating MT
May. 06 Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Travere Therapeutics : Equity Incentive Plan - Form 8-K
PU
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
GL
Travere Therapeutics to Present at Upcoming Investor Conferences
GL
Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating
MT
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : Travere Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024
Travere: Q1 Earnings Snapshot
AQ
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M
MT
Travere Therapeutics Reports First Quarter 2024 Financial Results
GL
Travere Therapeutics to Report First Quarter 2024 Financial Results
GL
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI for the treatment of IgA Nephropathy
AQ
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment
MT
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
GL
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
MT
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy
CI
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
GL
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
GL
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association
CI
North American Morning Briefing : Stocks Set for -2-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TVTX Stock
  4. News Travere Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW